Elsevier

Psychiatry Research

Volume 29, Issue 3, September 1989, Pages 361-362
Psychiatry Research

Cerebral glucose consumption measured by PET in patients with and without psychiatric symptoms of Huntington's disease

https://doi.org/10.1016/0165-1781(89)90090-5Get rights and content

References (9)

There are more references available in the full text version of this article.

Cited by (26)

  • Synaptopathic mechanisms of neurodegeneration and dementia: Insights from Huntington's disease

    2017, Progress in Neurobiology
    Citation Excerpt :

    SPECT studies show reduced blood flow in the cerebral cortex of pre-symptomatic HD individuals (Hasselbalch et al., 1992; Sax et al., 1996), which precedes cortical atrophy as evaluated by MRI (Jernigan et al., 1991). Moreover, PET studies have identified a reduced glucose uptake and metabolism in pre-symptomatic HD cerebral cortex (Hayden et al., 1986; Kuwert et al., 1989; Clark et al., 1991; Jenkins et al., 1998), indicating altered neuronal activity. Uric acid, glutathionine, and kyruneric acid, an antagonist of excitatory amino acid receptors, were also found to be reduced in HD post-mortem cortical tissue using high-performance liquid chromatography (Beal et al., 1992).

  • In vivo imaging of brain glutamate defects in a knock-in mouse model of Huntington's disease

    2016, NeuroImage
    Citation Excerpt :

    Defects in brain energy metabolism have been consistently found in HD patients and animal models. In particular, Positron Emission Tomography (PET) studies demonstrated large reduction in glucose consumption in the caudate/putamen in HD patients (Brouillet et al., 1999; Kuwert et al., 1989, 1990). Nonetheless, non-invasive in vivo methods to more broadly characterize energy metabolism in HD are rare.

  • PET: A revolution in medical imaging

    2004, Radiologic Clinics of North America
  • Implications of PET Based Molecular Imaging on the Current and Future Practice of Medicine

    2004, Seminars in Nuclear Medicine
    Citation Excerpt :

    Clearly, the introduction of molecular imaging techniques has revolutionized the field of oncology, which in turn has substantially contributed to the growth of the field of nuclear medicine.48 In particular, FDG-PET has definitely become necessary for the treatment of a variety of malignancies.48–51 Although FDG-PET plays an important role in staging various malignancies, its role in the diagnosis of cancer is limited at this time because most malignancies are diagnosed before FDG-PET is considered.

View all citing articles on Scopus
View full text